Zanolimumab

From Wikipedia, the free encyclopedia
Zanolimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target CD4
Clinical data
Legal status ?
Identifiers
CAS number 652153-01-0 N
ATC code None
UNII HG3L8885M0 YesY
KEGG D06356 YesY
Chemical data
Formula ?
Mol. mass 147 kDa
 N (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]

References

  1. ↑ Genmab initiates Phase II Study with HuMax-CD4
  2. ↑ http://www.tenxbiopharma.com/development.shtml
  3. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ↑ ClinicalTrials.gov NCT00042406 Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker
  5. ↑ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011. 
Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
antifolate: Methotrexate
Macrolides/
other IL-2 inhibitors
Other
Intracellular
(reception)
Extracellular
Monoclonal
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)

Monoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.